Veterinary Infectious Disease Therapeutics Market is estimated to increase at a Compounded Annual Growth Rate of 6.2% CAGR over the forecast period from 2024 to 2030
The Veterinary Infectious Disease Therapeutics Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Product (Antibiotics, Antiviral, Antifungal, Amebicides, Others), By Animal (Dogs and Cats, Horses, Swine, Poultry, Others).
An Introduction to Veterinary Infectious Disease Therapeutics Market in 2024
In 2024, the market for veterinary infectious disease therapeutics continues to be crucial in addressing the diverse array of infectious diseases affecting animals worldwide. Veterinary infectious disease therapeutics encompass a broad spectrum of treatment options, including antimicrobial agents, antivirals, antifungals, and immunomodulators, tailored to combat pathogens and bolster the immune response in animals. With advancements in antimicrobial research, vaccine development, and diagnostic testing, veterinary infectious disease therapeutics aim to prevent outbreaks, control disease spread, and improve animal health and welfare. Moreover, the market is influenced by trends such as the emergence of novel infectious agents, the evolution of antimicrobial resistance, and the implementation of One Health approaches to address interconnected human, animal, and environmental health challenges. Additionally, ongoing research focuses on developing next-generation vaccines, antiviral drugs, and immunotherapies, optimizing treatment protocols for specific pathogens and host species, and enhancing global surveillance and response systems to mitigate the impact of emerging infectious diseases on animal populations and public health.
Market Trend: Increasing Prevalence of Emerging Infectious Diseases in Animals
One prominent market trend in veterinary infectious disease therapeutics is the increasing prevalence of emerging infectious diseases in animals. With factors such as globalization, climate change, and changes in land use, there has been a rise in the incidence of novel infectious diseases affecting animals worldwide. These diseases pose significant health threats to both domestic and wild animal populations, leading to increased demand for effective therapeutics to prevent, manage, and control infectious diseases in veterinary medicine. The emergence of new pathogens and the spread of existing ones underscore the importance of ongoing research and development efforts to address evolving infectious disease challenges in animals.
Market Driver: Growing Awareness of Zoonotic Diseases and One Health Approach
A significant market driver for veterinary infectious disease therapeutics is the growing awareness of zoonotic diseases and the adoption of a One Health approach. Zoonotic diseases are infectious diseases that can be transmitted between animals and humans, posing public health risks and requiring collaborative efforts between human and veterinary healthcare professionals to address them. The One Health approach recognizes the interconnectedness of human, animal, and environmental health and emphasizes the need for interdisciplinary collaboration to prevent and control infectious diseases at the human-animal-environment interface. As awareness of zoonotic diseases increases and the importance of One Health principles gains recognition, there is heightened demand for effective veterinary therapeutics to mitigate the spread of zoonotic pathogens and safeguard both animal and human health.
Market Opportunity: Development of Broad-Spectrum Antimicrobial Agents and Vaccines
One potential opportunity in the veterinary infectious disease therapeutics market lies in the development of broad-spectrum antimicrobial agents and vaccines. With the emergence of antimicrobial resistance and the challenges associated with treating multidrug-resistant infections in animals, there is a need for novel antimicrobial agents that can effectively combat a wide range of pathogens. Additionally, the development of vaccines targeting key infectious agents can provide proactive protection against infectious diseases in animals, reducing the need for antimicrobial treatment and preventing disease transmission. By investing in the research and development of broad-spectrum antimicrobial agents and vaccines for veterinary use, pharmaceutical companies can capitalize on opportunities to address unmet medical needs, combat antimicrobial resistance, and contribute to the promotion of animal health and welfare.
Veterinary Infectious Disease Therapeutics Market Share Analysis: Antiviral Therapeutics for Poultry
In the Veterinary Infectious Disease Therapeutics Market, the segment experiencing rapid growth is Antiviral Therapeutics for Poultry. Poultry farming faces significant challenges related to infectious diseases, which can have detrimental effects on flock health and productivity. Antiviral therapeutics play a crucial role in controlling viral diseases such as avian influenza, Newcastle disease, and infectious bronchitis in poultry. The high susceptibility of poultry to viral infections, coupled with the potential economic losses associated with disease outbreaks, drives the demand for effective antiviral therapeutics in poultry production. Additionally, the globalization of poultry trade and the increasing demand for poultry products further emphasize the importance of disease prevention and treatment in maintaining the health and sustainability of poultry populations. With ongoing advancements in antiviral drug development and a growing focus on biosecurity measures in poultry farming, the market for antiviral therapeutics for poultry is expected to witness significant growth in the veterinary infectious disease therapeutics market.
Veterinary Infectious Disease Therapeutics Competitive Analysis
The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossBayer AG, Boehringer Ingelheim Vetmedica Inc, Ceva Santé Animale, Dechra Pharmaceuticals PLC, Elanco Animal Health, IDEXX Laboratories Inc, Merck & Co. Inc, Vetoquinol S.A., Virbac S.A., Zoetis Inc
Veterinary Infectious Disease Therapeutics Market Segmentation
By Product
Antibiotics
Antiviral
Antifungal
Amebicides
Others
By Animal
Dogs and Cats
Horses
Swine
Poultry
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Veterinary Infectious Disease Therapeutics Market Companies
Bayer AG
Boehringer Ingelheim Vetmedica Inc
Ceva Santé Animale
Dechra Pharmaceuticals PLC
Elanco Animal Health
IDEXX Laboratories Inc
Merck & Co. Inc
Vetoquinol S.A.
Virbac S.A.
Zoetis Inc
Reasons to Buy the Veterinary Infectious Disease Therapeutics Market Study
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Veterinary Infectious Disease Therapeutics Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Veterinary Infectious Disease Therapeutics Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Veterinary Infectious Disease Therapeutics Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Veterinary Infectious Disease Therapeutics Market Size Outlook, $ Million, 2021 to 2030
3.2 Veterinary Infectious Disease Therapeutics Market Outlook by Type, $ Million, 2021 to 2030
3.3 Veterinary Infectious Disease Therapeutics Market Outlook by Product, $ Million, 2021 to 2030
3.4 Veterinary Infectious Disease Therapeutics Market Outlook by Application, $ Million, 2021 to 2030
3.5 Veterinary Infectious Disease Therapeutics Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Veterinary Infectious Disease Therapeutics Industry
4.2 Key Market Trends in Veterinary Infectious Disease Therapeutics Industry
4.3 Potential Opportunities in Veterinary Infectious Disease Therapeutics Industry
4.4 Key Challenges in Veterinary Infectious Disease Therapeutics Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Veterinary Infectious Disease Therapeutics Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Veterinary Infectious Disease Therapeutics Market Outlook by Segments
7.1 Veterinary Infectious Disease Therapeutics Market Outlook by Segments, $ Million, 2021- 2030
By Product
Antibiotics
Antiviral
Antifungal
Amebicides
Others
By Animal
Dogs and Cats
Horses
Swine
Poultry
Others
8 North America Veterinary Infectious Disease Therapeutics Market Analysis and Outlook To 2030
8.1 Introduction to North America Veterinary Infectious Disease Therapeutics Markets in 2024
8.2 North America Veterinary Infectious Disease Therapeutics Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Veterinary Infectious Disease Therapeutics Market size Outlook by Segments, 2021-2030
By Product
Antibiotics
Antiviral
Antifungal
Amebicides
Others
By Animal
Dogs and Cats
Horses
Swine
Poultry
Others
9 Europe Veterinary Infectious Disease Therapeutics Market Analysis and Outlook To 2030
9.1 Introduction to Europe Veterinary Infectious Disease Therapeutics Markets in 2024
9.2 Europe Veterinary Infectious Disease Therapeutics Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Veterinary Infectious Disease Therapeutics Market Size Outlook by Segments, 2021-2030
By Product
Antibiotics
Antiviral
Antifungal
Amebicides
Others
By Animal
Dogs and Cats
Horses
Swine
Poultry
Others
10 Asia Pacific Veterinary Infectious Disease Therapeutics Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Veterinary Infectious Disease Therapeutics Markets in 2024
10.2 Asia Pacific Veterinary Infectious Disease Therapeutics Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Veterinary Infectious Disease Therapeutics Market size Outlook by Segments, 2021-2030
By Product
Antibiotics
Antiviral
Antifungal
Amebicides
Others
By Animal
Dogs and Cats
Horses
Swine
Poultry
Others
11 South America Veterinary Infectious Disease Therapeutics Market Analysis and Outlook To 2030
11.1 Introduction to South America Veterinary Infectious Disease Therapeutics Markets in 2024
11.2 South America Veterinary Infectious Disease Therapeutics Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Veterinary Infectious Disease Therapeutics Market size Outlook by Segments, 2021-2030
By Product
Antibiotics
Antiviral
Antifungal
Amebicides
Others
By Animal
Dogs and Cats
Horses
Swine
Poultry
Others
12 Middle East and Africa Veterinary Infectious Disease Therapeutics Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Veterinary Infectious Disease Therapeutics Markets in 2024
12.2 Middle East and Africa Veterinary Infectious Disease Therapeutics Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Veterinary Infectious Disease Therapeutics Market size Outlook by Segments, 2021-2030
By Product
Antibiotics
Antiviral
Antifungal
Amebicides
Others
By Animal
Dogs and Cats
Horses
Swine
Poultry
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Bayer AG
Boehringer Ingelheim Vetmedica Inc
Ceva Santé Animale
Dechra Pharmaceuticals PLC
Elanco Animal Health
IDEXX Laboratories Inc
Merck & Co. Inc
Vetoquinol S.A.
Virbac S.A.
Zoetis Inc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Product
Antibiotics
Antiviral
Antifungal
Amebicides
Others
By Animal
Dogs and Cats
Horses
Swine
Poultry
Others
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
